Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX-187 in Healthy Volunteers and Patients With a Bacterial Infection
NCT07708116Phase 1Recruiting
- Sponsor
- Centauri Therapeutics Limited
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABX-01 in bacterial infection and bronchiectasis (6 arms), sponsored by Centauri Therapeutics Limited. Primary endpoint: Treatment-emergent Adverse Events. Started Jun 2026; status: recruiting.
02
Drugs
ABX-01
03
Conditions
bacterial infectionbronchiectasis
Beyond the preview
Go deeper on NCT07708116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07708116.